SPR720: An Investigational Oral Candidate for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

Although rare, the incidence of NTM-PD is increasing worldwide with notable variation by geographic region.[4] Studies from North America, Europe, and Asia have all shown rising NTM rates over the last two decades.[8] Both host and climatic factors contribute to the disease, which imposes a substantial and often unappreciated burden of illness.[3] Host factors associated with increased susceptibility include preexisting conditions (e.g., bronchiectasis, rheumatoid arthritis, chronic obstructive pulmonary disease), age, race and/or ethnicity, and sex.[4] Although NTM is a relatively rare disease, it is a significant cause of morbidity among older adults, particularly women.[4]

Because NTM is not a reportable condition, alternative methods have been used to estimate disease burden, including analysis of large datasets using International Classification of Diseases, 9th Revision (ICD-9), codes and laboratory-based studies.[4] These measures have limitations. The chronic and slowly progressive nature of the disease, which requires treatment for at least 12-18 months, leads to costly prescription medications and recurring hospital visits due to relapse of reinfection. For a relatively rare disease, the financial burden of NTM disease is substantial, particularly among older adults.[4]

According to market industry analysis, the NTM infections market is poised for significant growth, with an estimated increase of USD $4.33 billion from 2023 to 2028, progressing at a compound annual growth rate of 5.66%. In 2014, the annual cost in the U.S. alone was estimated at $1.7 billion. Chronic morbidity, substantial mortality, and the economic costs of managing NTM-PD suggest a societal importance beyond what prevalence data suggests.[4]